Invited commentary: When and how to initiate systemic therapy in treating favorable risk metastatic renal cell carcinoma.
作者信息
Inoue Takahiro
机构信息
Department of Nehpro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.
出版信息
Curr Urol. 2021 Dec;15(4):185-186. doi: 10.1097/CU9.0000000000000052. Epub 2021 Oct 19.
Abstract
摘要
相似文献
1
Invited commentary: When and how to initiate systemic therapy in treating favorable risk metastatic renal cell carcinoma.
Curr Urol. 2021 Dec;15(4):185-186. doi: 10.1097/CU9.0000000000000052. Epub 2021 Oct 19.
2
Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy.
Korean J Urol. 2015 Mar;56(3):205-11. doi: 10.4111/kju.2015.56.3.205. Epub 2015 Mar 3.
3
An invited commentary on "Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis" [Int. J. Surg. 79 (2020) 66-73].
Int J Surg. 2020 Jul;79:324-325. doi: 10.1016/j.ijsu.2020.06.003. Epub 2020 Jun 11.
4
Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease.
Rare Tumors. 2013 Jul 5;5(3):e29. doi: 10.4081/rt.2013.e29. eCollection 2013.
5
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Oncologist. 2020 May;25(5):422-430. doi: 10.1634/theoncologist.2019-0605. Epub 2020 Jan 23.
6
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1.
7
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 2017 Feb;71(2):204-209. doi: 10.1016/j.eururo.2016.05.049. Epub 2016 Jun 16.
8
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.
9
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.
10
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Lancet Oncol. 2015 Mar;16(3):293-300. doi: 10.1016/S1470-2045(14)71222-7. Epub 2015 Feb 12.
引用本文的文献
1
Identification and validation of a gap junction protein related signature for predicting the prognosis of renal clear cell carcinoma.
Front Oncol. 2024 Feb 22;14:1354049. doi: 10.3389/fonc.2024.1354049. eCollection 2024.
本文引用的文献
1
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Cancer. 2021 Jul 1;127(13):2204-2212. doi: 10.1002/cncr.33494. Epub 2021 Mar 25.
2
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
3
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.
4
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
5
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.
6
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.
7
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Clin Cancer Res. 2008 Oct 15;14(20):6674-82. doi: 10.1158/1078-0432.CCR-07-5212.
8
Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.
Br J Urol. 1989 Feb;63(2):128-31. doi: 10.1111/j.1464-410x.1989.tb05147.x.
Zotero 插件